These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 35908883)
1. Prasugrel for Secondary Prevention of Thrombotic Stroke. Yagita Y J Atheroscler Thromb; 2023 Mar; 30(3):220-221. PubMed ID: 35908883 [No Abstract] [Full Text] [Related]
2. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191 [TBL] [Abstract][Full Text] [Related]
3. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study. Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028 [TBL] [Abstract][Full Text] [Related]
4. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database. Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197 [TBL] [Abstract][Full Text] [Related]
5. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB Curr Med Res Opin; 2014 Nov; 30(11):2207-16. PubMed ID: 25034466 [TBL] [Abstract][Full Text] [Related]
6. VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel. Cubero Gómez JM; Acosta Martínez J; Mendias Benítez C; Díaz De La Llera LS; Fernández-Quero M; Guisado Rasco A; Villa Gil-Ortega M; Sánchez González Á Acta Cardiol; 2015 Dec; 70(6):728-34. PubMed ID: 26717223 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III). Kitazono T; Kamouchi M; Matsumaru Y; Nakamura M; Umemura K; Matsuo H; Koyama N; Tsutsumi J; Kimura K J Atheroscler Thromb; 2023 Mar; 30(3):222-236. PubMed ID: 35599000 [TBL] [Abstract][Full Text] [Related]
9. Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. Verdoia M; Barbieri L; Suryapranata H; De Luca G Platelets; 2016; 27(2):93-104. PubMed ID: 25970631 [TBL] [Abstract][Full Text] [Related]
10. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Murphy SA; Antman EM; Wiviott SD; Weerakkody G; Morocutti G; Huber K; Lopez-Sendon J; McCabe CH; Braunwald E; Eur Heart J; 2008 Oct; 29(20):2473-9. PubMed ID: 18682445 [TBL] [Abstract][Full Text] [Related]
11. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry. Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. O'Connor SA; Amour J; Mercadier A; Martin R; Kerneis M; Abtan J; Brugier D; Silvain J; Barthélémy O; Leprince P; Montalescot G; Collet JP; Circ Cardiovasc Interv; 2015 Nov; 8(11):e002786. PubMed ID: 26553698 [TBL] [Abstract][Full Text] [Related]
13. Potent effect of prasugrel on acute phase resolution of intra-stent athero-thrombotic burden after percutaneous intervention to acute coronary syndrome. Tsukiyama Y; Kozuki A; Shinke T; Otake H; Kijima Y; Masano T; Nagoshi R; Shibata H; Takeshige R; Yanaka KI; Shite J; Hirata KI J Cardiol; 2018 Nov; 72(5):403-410. PubMed ID: 29731189 [TBL] [Abstract][Full Text] [Related]
14. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S; Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078 [TBL] [Abstract][Full Text] [Related]
15. High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. Geisler T; Booth J; Tavlaki E; Karathanos A; Müller K; Droppa M; Gawaz M; Yanez-Lopez M; Davidson SJ; Stables RH; Banya W; Zaman A; Flather M; Dalby M PLoS One; 2015; 10(8):e0135037. PubMed ID: 26317618 [TBL] [Abstract][Full Text] [Related]